India’s Reliance Industries Buys Stake in Balaji Telefilms
Indian conglomerate Reliance Industries Ltd. is acquiring a 24.9% stake in leading content provider Balaji Telefilms for $64.2 million, part of Reliance’s push into the entertainment sector. Balaji operates the digital content platform ALT and will use the Reliance investment to grow the business further.
Led by billionaire Mukesh Ambani, Reliance operates in the telecom, petroleum, retail, and media spheres. The group’s 2016 annual revenue was $44.7 billion.
Balaji Telefilms produces most of India’s top-rated Hindi-language television content, including “Naagin,” “Kum Kum Bhagya,” and “Ye Hai Mohabbatein.” The Balaji-produced “Chandrakanta” is currently airing on the Colors channel operated by Network 18, the media group in which Reliance owns a controlling stake.
“Lipstick Under My Burkha” (pictured), a film that initially ran afoul of Indian censors but was subsequently cleared, is being distributed from Friday by Balaji’s films division, Balaji Motion Pictures, alongside ALT.
“This investment in content production (including digital content) is in line with [our] commitment to invest and grow in telecom, digital, and media businesses,” Reliance said in a statement.
In 2014, the company acquired a controlling stake in Network 18, which operates several news, entertainment, and lifestyle channels, including Colors, CNBC TV 18, MTV India, VH1, Comedy Central, Nickelodeon, and History TV 18. Revenues for the Network 18 group in 2016 were $530 million.
2026-10-13
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Up to 25 billion! Saudi Aramco may acquire 20% of Reliance Industries
-
'RIL-Aramco stake sale talks stall over valuation, deal structure'
-
Profit Soars While Sales Dip: Syngenta Group Defies Headwinds with 28% EBITDA Surge in Q3 2025
-
BASF, Covestro, Huntsman Raise MDI Prices in North America Amid Global Supply Crunch
-
Growing Pains, But the Roots Are Strong: Corteva Narrows Losses Amid Sales Surge in Q3 2025
-
Novo Nordisk Enters High-Stakes Bidding War with Pfizer for Metsera
-
From the Brink to the Bend: Bayer’s Q3 2025 Shows Dramatic Loss Reduction—but Crop Science Still Bleeds
-
Yara’s Green Surge: Record Profits Fuelled by Precision, Not Just Prices
-
Pfizer Seen Holding Strategic Edge in Bidding Battle for Metsera
-
From Modest Gains to Massive Profits: Nutrien’s Q3 2025 Marks a Stunning Agricultural Comeback
Recommend Reading
-
Cipla CEO Calls Tirzepatide a High-Science Product with Strong Market Outlook
-
Pfizer Sues Metsera and Novo Nordisk Over Rival Obesity Drug Strategy
-
Syngenta Gets a New Boss
-
Syngenta Bee Pesticide Protest Shows the Pressure Building Around Crop Protection Giants
-
Bayer Wins Big on Roundup
-
After Two Rounds of Price Cuts, the Coke Market Stabilizes in China
-
Medicare’s $50 GLP-1 Door Opens: Weight-Loss Drug Demand Just Got Bigger
-
Business Society September 20, 2026 MTBE Trend Analysis: Volatile Consolidation
-
Downstream Demand Releases, Formic Acid Prices Steadily Rise
-
Business Society September 21, 2026 Diesel Trend Analysis: Weak Consolidation